Integra LifeSciences Announces $450 Million Senior Secured Notes Offering

PRINCETON, N.J., Oct. 09, 2026 /CourierPR/ -- Integra LifeSciences Holdings Corporation has announced the pricing of a significant financial transaction. The company is set to issue $450,000,000 in aggregate principal amount of 9.500% senior secured notes due in 2033. These notes will be general senior secured obligations of the company and will be guaranteed by the company’s wholly-owned domestic subsidiaries that are guarantors under the company’s senior secured credit facilities.

The sale of these notes is expected to close on or about October 19, 2026, subject to customary closing conditions. The company intends to use the net proceeds from the offering, together with borrowings under new credit facilities, to refinance its existing credit facilities and pay fees and expenses in connection with the transaction. This move is part of a broader refinancing strategy aimed at restructuring the company’s debt profile.

According to the press release, the notes and the related guarantees have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”). The offering is being made to persons reasonably believed to be qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A of the Securities Act and to certain non-U.S. persons outside of the United States in compliance with Regulation S of the Securities Act.

Integra LifeSciences is a global medical technology leader dedicated to restoring lives. The company’s portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. The transaction is part of the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives.

Forward-looking statements contained in the press release include, but are not limited to, the expectations, plans, and prospects for the company, including whether the company will consummate the offering of the notes on the expected terms or at all, the anticipated use of proceeds of the offering of the notes, market and other general economic conditions, and other risks identified under the heading “Risk Factors” included in Integra LifeSciences’ Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission.